London Health Sciences Centre
lhsc.on.caMatched: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London Health Sciences Centre · London Health Sciences Centre Research Institute
Live pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
741
Active
123
Phase 3
66
Total enrollment
805,305
Pipeline matrix
Showing 40 of 42 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Celecoxib | — | — | — | — | 2 | ||
| Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] | — | — | — | — | — | 1 | |
| Etanercept | — | — | — | — | — | 1 | |
| tofacitinib | — | — | — | — | — | 1 | |
| Epinephrine | — | — | — | — | — | 2 | |
| Transarterial Chemoembolization | — | — | — | — | — | 1 | |
| Midazolam Nasal Spray | — | — | — | — | — | 1 | |
| Nitrous oxide | — | — | — | — | — | 1 | |
| Heparin | — | — | — | — | — | 1 | |
| Placebos | — | — | — | — | — | 1 | |
| calcium gluconate | — | — | — | — | — | 1 | |
| Control: Placebo | — | — | — | — | — | 1 | |
| Dexmedetomidine | — | — | — | 4 | |||
| Brentuximab Vedotin | — | — | — | — | — | 2 | |
| Interdialytic peritoneal ultrafiltration with 10% dextrose solution | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Experimental | — | — | — | — | — | 1 | |
| Tamsulosin Hydrochloride | — | — | — | — | — | 1 | |
| Ambroxol Hydrochloride | — | — | — | — | — | 1 | |
| AV-001 or Placebo | — | — | — | — | — | 1 | |
| Concurrent Chemotherapy | — | — | — | — | — | 1 | |
| UVADEX | — | — | — | — | — | 1 | |
| Genistein | — | — | — | — | — | 1 | |
| Pirfenidone 267 MG [Esbriet] | — | — | — | — | — | 1 | |
| Fecal Microbiota Transplantation | — | — | — | — | — | 1 | |
| Fecal Microbial Transplantation | — | — | — | — | — | 1 | |
| Trazodone | — | — | — | — | — | 1 | |
| Quetiapine | — | — | — | — | — | 1 | |
| Levocarnitine | — | — | — | — | — | 1 | |
| Furosemide | — | — | — | — | 2 | ||
| Ropivacaine and Lidocaine | — | — | — | — | — | 1 | |
| Ropivacaine 0,5% | — | — | — | — | — | 1 | |
| Cenergermin | — | — | — | — | — | 1 | |
| Desmopressin after protamine reversal | — | — | — | — | — | 1 | |
| High-Dose Cisplatin | — | — | — | — | — | 1 | |
| Low-Dose Cisplatin | — | — | — | — | — | 1 | |
| Fecal Microbial transplant | — | — | — | — | — | 1 | |
| Pharmacogenetic testing | — | — | — | — | — | 1 | |
| Postoperative antibiotico-prophylaxis | — | — | — | — | — | 1 | |
| Pharmacogenetics Testing | — | — | — | — | — | 1 |
2 more active programs hidden
Next readouts
- 2021-09-14
- 2023-11-28
- 2023-12-14
- 2025-03
- 2025-08-01
- 2025-09
- 2025-09-01
- 2025-09-01
- 2025-12-30
- 2025-12-31
Top conditions
- Prostate Cancer17
- Depression16
- Anxiety13
- Stroke12
- Coronary Artery Disease11
- Hemodialysis10
- Knee Osteoarthritis10
- Heart Failure10
Frequently asked questions about London Health Sciences Centre
- How many clinical trials does London Health Sciences Centre have on ClinicalTrials.gov?
- London Health Sciences Centre is listed as the lead sponsor on 741 clinical trials in ClinicalTrials.gov, 123 of which are currently active (recruiting, enrolling, or ongoing).
- How many of London Health Sciences Centre's trials are in Phase 3?
- 66 of London Health Sciences Centre's trials are in Phase 3, spread across 42 active drug programs.
- What therapeutic areas does London Health Sciences Centre focus on?
- London Health Sciences Centre's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Depression, Anxiety, Stroke, Coronary Artery Disease.
- When are London Health Sciences Centre's next clinical trial readouts?
- London Health Sciences Centre has 10 upcoming primary-completion readouts tracked here; the soonest is “Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)”, expected around 2021-09-14.